ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > transfer pmn.to to NASDAQ

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Aug 23, 2023 10:38am

86 Views

Post# 35601732

RE:transfer pmn.to to NASDAQ

bakerlakeboy wrote: I have a handful of shares of pmn.to through Questrade. I expected when they consolidated to NASDAQ that the shares would transfer over on July 21 but that hasnt happened yet. Did you have to call your exchange to get them transferred? What was your experience, TIA

You need to call them and wake them up!

It took my brokerages approximately 3 weeks to make the changes on my part.

G1945V

<< Previous

Bullboard Posts

Next >>

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!